NeutroSpec Promos Tout Broad, Unsupported Indications, FDA Chides
This article was originally published in The Pink Sheet Daily
Executive Summary
The withdrawn imaging agent is cited for violations made during the 2005 American Pharmaceutical Association annual meeting.
You may also be interested in...
NeutroSpec Pulled From The Market
FDA "reconsidered" the risk/benefit balance for Mallinckrodt/Palatin Technologies' appendicitis imaging agent, which has been associated with cardiopulmonary events.
Raising Corporate Taxes Would Put US Investment At Risk, J&J CFO Warns
Raising US corporate taxes would reduce corporate investment in the US and particularly impact jobs, Johnson & Johnson chief financial officer Joseph Wolk cautioned during the company's first quarter sales and earnings call on 20 April.
J&J, Hopeful On COVID-19 Vaccine Outlook, Looks To Restore Public Confidence
The company recorded $100m in revenues from the vaccine in the first quarter, before administration was paused in the US and Europe to review a rare risk of blood clots.